Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice
1996

Impact of Cremophor on Doxorubicin in Mice

Sample size: 30 publication Evidence: moderate

Author Information

Author(s): LK Webster, EJ Cosson, KH Stokes, MJ Millward

Primary Institution: Peter MacCallum Cancer Institute

Hypothesis

Cremophor EL affects the pharmacokinetics of doxorubicin and doxorubicinol in mice.

Conclusion

Cremophor significantly increases the bioavailability of doxorubicin and its metabolite doxorubicinol in mice.

Supporting Evidence

  • Cremophor increased doxorubicin AUC from 1420 to 2770 ng h ml-'.
  • Doxorubicinol AUC increased from 130 to 320 ng h ml-'.
  • Plasma concentrations of doxorubicin were higher at all time points with Cremophor.

Takeaway

Cremophor helps a medicine called doxorubicin work better in mice, which might make it stronger but could also cause more side effects.

Methodology

Mice were given either Cremophor or saline before receiving doxorubicin, and plasma levels were measured at various time points.

Limitations

The study was conducted in mice, and the effects in humans may differ.

Participant Demographics

Female Balb/c mice, aged 9-12 weeks, weighing 18-24g.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication